ACROBiosystems EU

An internationally recognised manufacturer of recombinant proteins and other critical reagents to support target therapeutics, vaccines, and diagnostics.

[ACROBiosystems EU @AcrobiosystemsE]

When conducting immunological research, choosing the appropriate isotype control is crucial for ensuring accurate and reliable results. We provide IgG Isotype Controls, IgG Fc Proteins, and Recombinant Serum Albumin to empower drug research. Click: https://t.co/IuHMmq7fbg

[ACROBiosystems EU @AcrobiosystemsE]

To help drug developers and researchers screen TL1A inhibitors more efficiently, ACROBiosystems has launched TL1A [Biotinylated] : DR3 Inhibitor Screening ELISA Kit, providing strong support for your biologics development process! Click to explore: https://t.co/rhd36yjdDc

[ACROBiosystems EU @AcrobiosystemsE]

The development of FcRn-targeted therapies for autoimmune diseases presents vast and promising prospect. We are excited to offer diverse FcRn products for supporting your drug development journey! Click to explore more: https://t.co/D0KGvV79hs

[ACROBiosystems EU @AcrobiosystemsE]

CD3/CD20 bispecific antibodies (BsAbs) are making significant strides in cancer treatment. These antibodies combine potent therapeutic effects with a favorable safety profile, fueling increasing market. https://t.co/05rT4cCUQF

[ACROBiosystems EU @AcrobiosystemsE]

On 14 August, 2024, the WHO has declared the ongoing Mpox outbreak a Public Health Emergency of International Concern (PHEIC).The need for more effective monkeypox vaccine is urgent. Explore core reagents for MPXV vaccine research: https://t.co/n7DqdbOYHz

[ACROBiosystems EU @AcrobiosystemsE]

To meet the development needs of hypercholesterolemia inhibitors, ACROBiosystems offers PCSK9 recombinant proteins to support your LDL-C-lowering inhibitors development!
For detail information: https://t.co/tawtYTASy7

[ACROBiosystems EU @AcrobiosystemsE]

Recent progress in Integrin and TL1A research for autoimmune diseases has sparked significant interest from major pharmaceutical companies. ACROBiosystems provides a range of tools for addressing IBD drug development needs effectively. Click: https://t.co/gx6LfYdWQM

[ACROBiosystems EU @AcrobiosystemsE]

Neural antibodies can specifically bind with biomarkers on nerve cells, helping researchers to not only identify nerve cell types but also monitor their alterations in neurodegenerative diseases, facilitating diagnosis and therapeutic development. Click: https://t.co/9zaPgh1uG7

[ACROBiosystems EU @AcrobiosystemsE]

Streptavidin (SA), as a widely used signal amplification reagent, boasts unique binding specificity, high affinity, and exceptional stability, enabling it to form robust complexes with biotinylated probes or antibodies. Click: https://t.co/UpUpODEbJH

[ACROBiosystems EU @AcrobiosystemsE]

In 2023, there were four significant transactions in the global autoimmune disease field, three of which were related to the TL1A target. To meet the demands for developing targeted TL1A / DR3 antibody drug, click for more information: https://t.co/ai81L99UGI

[ACROBiosystems EU @AcrobiosystemsE]

Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) technology can increase precision to accelerate efficient screening and optimization, ACROBiosystems proudly presents Human FcRn Binding Kit to promote your research.
Request free sample: https://t.co/xaTdNepnEW

[ACROBiosystems EU @AcrobiosystemsE]

VZV glycoprotein E (gE) is a crucial protective antigen, inducing both cellular and humoral immunity during natural infection. Additionally, the gI/gE, gH/gL heterodimer emerges as promising targets for novel VZV vaccines.
Click: https://t.co/ZqGrEoWZfg

[ACROBiosystems EU @AcrobiosystemsE]

Our high-activity CTSB facilitates evaluation of ADC linker cleavage efficiency, driving groundbreaking research on Cathepsin B-mediated ADCs for targeted cancer therapy.
#ADCs #CancerResearch #CathepsinB #CleaveableLinkers

[ACROBiosystems EU @AcrobiosystemsE]

ACROBiosystems has developed high-quality Recombinant Proteins, Antibodies, Functional Cell Lines, and Inhibitor Screening Kits drug development tools including the targets for the development of immunomodulatory drugs.
Learn more: https://t.co/79I3Eu7PQe

[ACROBiosystems EU @AcrobiosystemsE]

ACROBiosystems' Organoid Toolbox offers physiologically-relevant infection conditions, enabling more accurate assessment of AAV vector performance for gene therapy applications.
Click to discover more about the Organoid Toolbox: https://t.co/pXK5YbUIff

[ACROBiosystems EU @AcrobiosystemsE]

Introducing PFFs into brain organoid models offers a significant advancement in AD research. This approach closely mimics the pathological proteins seeding and propagation observed in AD, leading to a more realistic disease model.
Explore more: https://t.co/86LuiKVg0O

[ACROBiosystems EU @AcrobiosystemsE]

In 2023, semaglutide was undoubtedly Novo Nordisk's star product, while tirzepatide was Eli Lilly's most anticipated product. To meet the needs for diabetes and weight loss, ACROBiosystems developed high-quality GLP-1R products!
Learn more: https://t.co/2MrqSZNeKW

[ACROBiosystems EU @AcrobiosystemsE]

CD63, a tetraspanin protein, whose role in exosomes biogenesis makes it a promising biomarker for cancers. ACROBiosystems offers full-length CD63 proteins (Ala 2-Met 238) via "FLAG", to support research and drugs.
More information: https://t.co/BTlHulNPi9

[ACROBiosystems EU @AcrobiosystemsE]

Aneuro, a neuroscience-focused brand by ACROBiosystems, empowers researchers by offering high-quality protein products and an array of more ready-to-use tools.
>>Explore Aneuro to Empower Your Research: https://t.co/ZFoxAPeNSz

[ACROBiosystems EU @AcrobiosystemsE]

ACROBiosystems has successfully developed HEK293 expressed full-length CD63-VLP protein (Ala 2-Met 238) via "FLAG" to support drugs and therapies R&D targeting CD63.

>>Explore Our Transmembrane Proteins Portfolio: https://t.co/3JMVVAQtz5